Rare Neurodegenerative Disease Treatment Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2030

Published on : Oct-2020 | List of Tables : 30 | List of Figures : 78 | No. of Pages : 170 | Report Code : FACT5197MR |

Global Rare Neurodegenerative Disease Treatment Market Overview

Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.

The global rare neurodegenerative disease treatment market size is anticipated to expand at a steady rate to surpass a valuation of US$ 116 billion by 2030-end. The COVID-19 pandemic is expected to have a moderate impact on the market. Advances in medical technology for the diagnosis and treatment of these ailments will contribute to long-term growth.

Rare Neurodegenerative Disease Treatment Market Insights by Indication

Neurodegenerative diseases can arise from deposits of toxins in brain tissue or alternatively through genetic mutations, or misfolded protein in the body’s neural network, which can result in a range of illnesses. The rare neurodegenerative disease treatment market has been divided into varying indications, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, acute migraine, autism, narcolepsy, amyotrophic lateral sclerosis, attention deficit hyperactivity disorder, spinal muscular atrophy, Tourette syndrome, and others.

The leading indication of rare neurodegenerative diseases, which holds a majority market share, is from multiple sclerosis, with increasing cases across North America and Europe. Alzheimer’s disease and Parkinson’s disease also account for substantial market share, with increased research investments, which is a major growth influencer.

Rare Neurodegenerative Disease Treatment Market Insights by Drug Class

The global rare neurodegenerative disease treatment market is primarily segmented according to drug class into neurotransmitter agents, neuroprotective agents, and biologics. Out of these, neuroprotective agents are estimated to account for a larger market share on the back of lower toxicity in comparison to conventional synthetic drugs.

The use of plant polyphenols aids neurotransmitter regulation and regular functioning of neurotransmitter receptors. Also, these drugs provide antioxidant benefits, which widens the scope of therapeutic applications, aiding growth in the market.

Rare Neurodegenerative Disease Treatment Market Insights by Distribution Channel

In the rare neurodegenerative disease treatment market, drugs are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Out of these channels, hospital pharmacies account for significant rare neurodegenerative disease treatment market share.

Growth of this segment can be primarily attributed to the availability of critical drugs, robust supply chains, and larger volumes of inventory being maintained by relevant hospital facilities in the industry.

rare neurodegenerative disease treatment market market growth analysis

For more valuable information on the rare neurodegenerative disease treatment market, request a report sample

Regional Outlook of Rare Neurodegenerative Disease Treatment Market

The global rare neurodegenerative disease treatment market is divided into the following regions – North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is likely to remain a prominent market for rare neurodegenerative disease treatment, with efforts by major market players to consolidate their position through strategic mergers and acquisitions.

Europe is also projected to reflect strong growth on the back of growing incidence of neurodegenerative diseases, while Asia Pacific will generate lucrative opportunities with increased investments in healthcare modernization initiatives in China and India, coupled with the growth of medical tourism in the region.

Rare Neurodegenerative Disease Treatment Market: Key Players

The global rare neurodegenerative disease treatment market is fairly fragmented in nature, characterized by the presence of numerous small-scale players in regional markets. Leading players in the market include Allergan Plc, Bayer AG, F.Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Manufacturers in the rare neurodegenerative disease treatment market are increasingly emphasizing on investments towards product development and launches, with improvements in functionality and accuracy of results.

  • For instance, Ionis Pharmaceuticals announced the receipt of FDA approval of Orphan Drug status for its ION373 treatment for Alexander Disease.
  • Similarly, Orphazyme A/S announced the acceptance of New Drug Application for arimoclomol as a viable treatment for Type C Niemann-Pick disease.
  • Also, PTC Therapeutics launched PTC Pinpoint, which is a genetic testing program for detecting neurotransmitter disorders.
rare neurodegenerative disease treatment market competition analysis

For a dashboard view of key players operating in the rare neurodegenerative disease treatment market, request a expert analyst

The Analyst’s Viewpoint

“A number of drug candidates for rare neurodegenerative disease treatments in research & development and clinical trial settings have revealed promising results. Consequently, major pharmaceutical manufacturers are expected to leverage these opportunities in the near future, through investments in product development and strategic collaborations.”

COVID-19 Impact on Rare Neurodegenerative Disease Treatment Market

Recent research has shown that the effects of COVID-19 on people suffering from rare neurodegenerative disorders is largely unpredictable. For instance, neuropathology of Parkinson’s disease has been found to potentially reduce symptoms of the COVID-19 virus. On the other hand, patients suffering from multiple sclerosis are at higher risk.

In addition, progression of neurodegeneration and long-term impacts of COVID-19 are yet to be discovered, with neurological ailments increasing the severity of acute respiratory syndrome. Further, redirection of medical resources for COVID-19 treatment and restrictions on in-person consultations are likely to have an adverse impact on the rare neurodegenerative disease treatment market in the short term, while creating lucrative opportunities through telehealth mediums.

Rare Neurodegenerative Disease Treatment Market: About the Report

Fact.MR has published an exclusive report on forecast data on the global rare neurodegenerative disease treatment market for the period of 2020 and 2030. A key objective of this study on the rare neurodegenerative disease treatment market is to generate actionable insights on the market scenario, demand influencers, and technological improvements in the industry. Further, the report on discusses essential dynamics that are likely to affect the future and sales of leading neurodegenerative treatment options.

The report on the global rare neurodegenerative disease treatment market starts with an executive overview, which includes precise product definition. The report also provides the taxonomy of the rare neurodegenerative disease treatment market, with comprehensive details on key segments. Also, the study provides actionable insights on the dynamics of the rare neurodegenerative disease treatment market, including the drivers, restraints, opportunities, and trends, in addition to pricing analysis and major purchase influencers for relevant treatments. Pricing analysis and supply chain analysis in addition to major differences in rare neurodegenerative disease treatments have been added to the report to aid readers in gaining clearer understanding the product framework map in the global rare neurodegenerative disease treatment market.

Rare Neurodegenerative Disease Treatment Market – Report Scope

Fact.MR recently published a report on the global market for rare neurodegenerative disease treatments. The study gives a clear assessment of critical market dynamics, including the drivers, trends, opportunities, and restraints, in addition to detailed data about the structure of the rare neurodegenerative disease treatment market. The market study presents exclusive information about how the rare neurodegenerative disease treatment market will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include year-on-year (Y-o-Y) growth of the market and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in detail. This information can help readers understand the quantitative growth prospects of the rare neurodegenerative disease treatment market during the forecast period.

The study is relevant for stakeholders in the rare neurodegenerative disease treatment market, including manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the rare neurodegenerative disease treatment market, investors, industry experts, researchers, and journalists, as well as business researchers, can leverage the information and data presented in Fact.MR’s study.

It also offers actionable insights based on the future trends in the rare neurodegenerative disease treatment market. Furthermore, small businesses and new entrants in the rare neurodegenerative disease treatment market too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Segments of Rare Neurodegenerative Disease Treatment Market

Fact.MR’s study on the rare neurodegenerative disease treatment market offers information divided into four important segments — indication, drug class, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Indication

Drug Class

Distribution Channel

Region

  • Multiple Sclerosis
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Spinal Muscular Atrophy
  • Tourette Syndrome
  • Huntington’s Disease
  • Others
  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Questions Answered in Fact.MR’s Rare Neurodegenerative Disease Treatment Market Report

  • Which regions will remain the most profitable regional markets for rare neurodegenerative disease treatment market players?
  • Which factors will induce a change in the demand for rare neurodegenerative disease treatments during the assessment period?
  • How will changing trends impact the rare neurodegenerative disease treatment market?
  • How can market players capture the low-hanging opportunities in the rare neurodegenerative disease treatment market in developed regions?
  • Which companies are leading the rare neurodegenerative disease treatment market?
  • What are the winning strategies of stakeholders in the rare neurodegenerative disease treatment market to upscale their position in this landscape?
  • What is the impact of the COVID-19 pandemic on the rare neurodegenerative disease treatment market?

Rare Neurodegenerative Disease Treatment Market: Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the rare neurodegenerative disease treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the rare neurodegenerative disease treatment market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the rare neurodegenerative disease treatment market, and makes Fact.MR’s projections on the growth prospects of the rare neurodegenerative disease treatment markets more accurate and reliable.

1. Executive Summary

    1.1. Summary of Key Findings

    1.2. Summary of Statistics 

    1.3. Fact.MR Analysis and Recommendations

2. Market Overview

    2.1. Market Introduction

    2.2. Market Definition 

    2.3. Market Taxonomy

3. Market Risks & Trends Assessment

    3.1. COVID-19 Impact Benchmark with Previous Crisis  

        3.1.1. Change in Rare Neurodegenerative Disease Treatment Demand and Consumption Growth

        3.1.2. Before and After COVID-19 Crisis (Projected)

        3.1.3. Before and after SARS Pandemic (Actual)

        3.1.4. Before and After Sub-prime Crisis – 2008 (Actual)

        3.1.5. Change in Demand post Recovery Period (After Each Crisis)

    3.2. Impact on Market Value (US$ Mn)

        3.2.1. Likely Loss of Value in 2020

        3.2.2. Mid-term and Long-Term Forecast

        3.2.3. Quarter by Quarter Dip and Recovery Assessment 

    3.3. Anticipated Demand and Value Recovery Curve

        3.3.1. Likelihood of U-Shape Recovery

        3.3.2. Likelihood of L-Shape Recovery

    3.4. Recovery Period Assessment by Key Countries

4. Market Background and Associated Industry Indicators

    4.1. Global Pharmaceutical Industry Outlook

        4.1.1. Key Trends in Pharmaceuticals Market

        4.1.2. Pharmaceuticals Market, by Region

        4.1.3. Pharmaceuticals Market, by Competition

    4.2. Forecast Factors - Relevance & Impact for Rare Neurodegenerative Disease Treatment

        4.2.1. Key Market Players Historic Growth

        4.2.2. Pharmaceutical Industry Growth Outlook

        4.2.3. Others

    4.3. Value Chain Analysis and Operating Margins 

        4.3.1. List of Raw Material Suppliers

        4.3.2. List of Key Manufacturers

        4.3.3. List of End-users

        4.3.4. Profit Margins 

        4.3.5. Notes on Value Added at Each Node in the Value Chain

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints and Market Risks

        4.4.3. Opportunity Analysis

5. Global Rare Neurodegenerative Disease Treatment Market Demand Analysis 2015-2020 and Forecast, 2020-2030

    5.1. Historical Market Analysis, 2015-2020

    5.2. Current and Future Market Projections, 2020-2030

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Global Rare Neurodegenerative Disease Treatment Market - Pricing Analysis

    6.1. Regional Pricing Analysis 

    6.2. Pricing Break-up

    6.3. Global Average Pricing Analysis Benchmark

7. Global Rare Neurodegenerative Disease Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2020 and Forecast, 2020-2030

    7.1. Historical Market Value (US$ Mn) Analysis, 2015-2020

    7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030, By Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) and Analysis by Indication, 2015 - 2020

    8.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Indication, 2020 - 2030

        8.3.1. Multiple Sclerosis

        8.3.2. Alzheimer’s Disease

        8.3.3. Parkinson Disease

        8.3.4. Acute Migraine

        8.3.5. Autism

        8.3.6. Narcolepsy

        8.3.7. Amyotrophic Lateral Sclerosis (ALS)

        8.3.8. Attention Deficit Hyperactivity Disorder (ADHD)

        8.3.9. Spinal Muscular Atrophy

        8.3.10. Tourette Syndrome

        8.3.11. Huntington’s Disease

        8.3.12. Others

    8.4. Market Attractiveness Analysis by Indication

9. Global Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030, By Drug Class

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) and Analysis by Drug Class, 2015 - 2020

    9.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Drug Class, 2020 - 2030

        9.3.1. Neurotransmitter Agents

        9.3.2. Neuroprotective Agents

        9.3.3. Biologics

        9.3.4. Others

      9.4. Market Attractiveness Analysis by Drug Class

10. Global Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) and Analysis by Distribution Channel, 2015 - 2020

    10.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Distribution Channel, 2020 - 2030

        10.3.1. Hospital Pharmacies

        10.3.2. Online Pharmacies

        10.3.3. Retail Pharmacies

10.4. Market Attractiveness Analysis by Distribution Channel

11. Global Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030, By Region 

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) and Analysis by Region, 2015 - 2020

    11.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Region, 2020 – 2028

        11.3.1. North America

        11.3.2. Europe 

        11.3.3. Asia Pacific

        11.3.4. Latin America

        11.3.5. Middle East & Africa 

12. North America Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

    12.1. Introduction

    12.2. Pricing Analysis

    12.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2015 - 2020

    12.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2020 - 2030

        12.4.1.  By Country

            12.4.1.1. U.S.

            12.4.1.2. Canada

        12.4.2. By Indication

        12.4.3. By Drug Class

        12.4.4. By Distribution Channel

12.5. Market Attractiveness Analysis

        12.5.1. By Country

        12.5.2. By Indication

        12.5.3. By Drug Class

        12.5.4. By Distribution Channel

    12.6. Market Trends

    12.7. Key Market Participants - Intensity Mapping

    12.8. Drivers and Restraints - Impact Analysis

13. Europe Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

     13.1. Introduction

    13.2. Pricing Analysis

    13.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2015 - 2020

    13.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2020 - 2030

        13.4.1.  By Country

         13.4.1.1. Germany

         13.4.1.2. U.K.

         13.4.1.3. France

         13.4.1.4. Spain

         13.4.1.5. Italy

         13.4.1.6. Rest of Europe

        13.4.2. By Indication

        13.4.3. By Drug Class

        13.4.4. By Distribution Channel

13.5. Market Attractiveness Analysis

        13.5.1. By Country

        13.5.2. By Indication

        13.5.3. By Drug Class

        13.5.4. By Distribution Channel

    13.6. Market Trends

    13.7. Key Market Participants - Intensity Mapping

    13.8. Drivers and Restraints - Impact Analysis

14. Asia Pacific Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

     14.1. Introduction

    14.2. Pricing Analysis

    14.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2015 - 2020

    14.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2020 - 2030

        14.4.1.  By Country

         14.4.1.1. Japan

         14.4.1.2. China

         14.4.1.3. India

         14.4.1.4. Australia & New Zealand

         14.4.1.5. Rest of Asia Pacific

     14.4.2. By Indication

        14.4.3. By Drug Class

        14.4.4. By Distribution Channel

14.5. Market Attractiveness Analysis

        14.5.1. By Country

        14.5.2. By Indication

        14.5.3. By Drug Class

        14.5.4. By Distribution Channel

    14.6. Market Trends

    14.7. Key Market Participants - Intensity Mapping

    14.8. Drivers and Restraints - Impact Analysis

15. Latin America Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

    15.1. Introduction

    15.2. Pricing Analysis

    15.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2015 - 2020

    15.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2020 - 2030

        15.4.1.  By Country

         15.4.1.1. Brazil

         15.4.1.2. Mexico

         15.4.1.3. Rest of Latin America

        15.4.2. By Indication

        15.4.3. By Drug Class

        15.4.4. By Distribution Channel

15.5. Market Attractiveness Analysis

        15.5.1. By Country

        15.5.2. By Indication

        15.5.3. By Drug Class

        15.5.4. By Distribution Channel

    15.6. Market Trends

    15.7. Key Market Participants - Intensity Mapping

    15.8. Drivers and Restraints - Impact Analysis

16. Middle East and Africa Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

    16.1. Introduction

    16.2. Pricing Analysis

    16.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2015 - 2020

    16.4. Market Size (US$ Mn) and Forecast by Market Taxonomy, 2020 - 2030

        16.4.1.  By Country

         16.4.1.1. GCC Countries

         16.4.1.2. South Africa

         16.4.1.3. Rest of Middle East and Africa

        16.4.2. By Indication

        16.4.3. By Drug Class

        16.4.4. By Distribution Channel

16.5. Market Attractiveness Analysis

        16.5.1. By Country

        16.5.2. By Indication

        16.5.3. By Drug Class

        16.5.4. By Distribution Channel

    16.6. Market Trends

    16.7. Key Market Participants - Intensity Mapping

    16.8. Drivers and Restraints - Impact Analysis

17. Key Countries Rare Neurodegenerative Disease Treatment Market Analysis 2015-2020 and Forecast 2020-2030

    17.1. Introduction

        17.1.1. Market Value Proportion Analysis, By Key Countries

        17.1.2. Global Vs. Country Growth Comparison

    17.2. U.S. Rare Neurodegenerative Disease Treatment Market Analysis

        17.2.1. Pricing Analysis

        17.2.2. Market Value Proportion Analysis by Market Taxonomy

        17.2.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.2.3.1.   By Indication

            17.2.3.2.   By Drug Class

            17.2.3.3.   By Distribution Channel

    17.3. Canada Rare neurodegenerative disease treatment Market Analysis

        17.3.1. Pricing Analysis

        17.3.2. Market Value Proportion Analysis by Market Taxonomy

        17.3.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.3.3.1.   By Indication

            17.3.3.2.   By Drug Class

            17.3.3.3.   By Distribution Channel

    17.4. Germany Rare Neurodegenerative Disease Treatment Market Analysis

        17.4.1. Pricing Analysis

        17.4.2. Market Value Proportion Analysis by Market Taxonomy

        17.4.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.4.3.1.   By Indication

            17.4.3.2.   By Drug Class

            17.4.3.3.   By Distribution Channel

    17.5. U.K. Rare Neurodegenerative Disease Treatment Market Analysis

        17.5.1. Pricing Analysis

        17.5.2. Market Value Proportion Analysis by Market Taxonomy

        17.5.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.5.3.1.   By Indication

            17.5.3.2.   By Drug Class

            17.5.3.3.   By Distribution Channel

    17.6. France Rare Neurodegenerative Disease Treatment Market Analysis

        17.6.1. Pricing Analysis

        17.6.2. Market Value Proportion Analysis by Market Taxonomy

        17.6.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.6.3.1.   By Indication

            17.6.3.2.   By Drug Class

            17.6.3.3.   By Distribution Channel

    17.7. Spain Rare Neurodegenerative Disease Treatment Market Analysis

        17.7.1. Pricing Analysis

        17.7.2. Market Value Proportion Analysis by Market Taxonomy

        17.7.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.7.3.1.   By Indication

            17.7.3.2.   By Drug Class

            17.7.3.3.   By Distribution Channel

    17.8. Italy Rare Neurodegenerative Disease Treatment Market Analysis

        17.8.1. Pricing Analysis

        17.8.2. Market Value Proportion Analysis by Market Taxonomy

        17.8.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.8.3.1.   By Indication

            17.8.3.2.   By Drug Class

            17.8.3.3.   By Distribution Channel

    17.9. Japan Rare Neurodegenerative Disease Treatment Market Analysis

        17.9.1. Pricing Analysis

        17.9.2. Market Value Proportion Analysis by Market Taxonomy

        17.9.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.9.3.1.    By Indication

            17.9.3.2.   By Drug Class

            17.9.3.3.   By Distribution Channel

    17.10. China Rare Neurodegenerative Disease Treatment Market Analysis

        17.10.1. Pricing Analysis

        17.10.2. Market Value Proportion Analysis by Market Taxonomy

        17.10.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.10.3.1.   By Indication

            17.10.3.2.   By Drug Class

            17.10.3.3.   By Distribution Channel

    17.11. India Rare Neurodegenerative Disease Treatment Market Analysis

        17.11.1. Pricing Analysis

        17.11.2. Market Value Proportion Analysis by Market Taxonomy

        17.11.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.11.3.1.   By Indication

            17.11.3.2.   By Drug Class

            17.11.3.3.   By Distribution Channel

    17.12. Australia & New Zealand Rare Neurodegenerative Disease Treatment Market Analysis

        17.12.1. Pricing Analysis

        17.12.2. Market Value Proportion Analysis by Market Taxonomy

        17.12.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.12.3.1.   By Indication

            17.12.3.2.   By Drug Class

            17.12.3.3.   By Distribution Channel

    17.13. Brazil Rare Neurodegenerative Disease Treatment Market Analysis

        17.13.1. Pricing Analysis

        17.13.2. Market Value Proportion Analysis by Market Taxonomy

        17.13.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.13.3.1.   By Indication

            17.13.3.2.   By Drug Class

            17.13.3.3.   By Distribution Channel

17.14. Brazil Rare Neurodegenerative Disease Treatment Market Analysis

        17.14.1. Pricing Analysis

        17.14.2. Market Value Proportion Analysis by Market Taxonomy

        17.14.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.14.3.1.   By Indication

            17.14.3.2.   By Drug Class

            17.14.3.3.   By Distribution Channel

17.15. Mexico Rare Neurodegenerative Disease Treatment Market Analysis

        17.15.1. Pricing Analysis

        17.15.2. Market Value Proportion Analysis by Market Taxonomy

        17.15.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.15.3.1.   By Indication

            17.15.3.2.   By Drug Class

            17.15.3.3.   By Distribution Channel 

17.16. GCC Countries Rare Neurodegenerative Disease Treatment Market Analysis

        17.16.1. Pricing Analysis

        17.16.2. Market Value Proportion Analysis by Market Taxonomy

        17.16.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.16.3.1.   By Indication

            17.16.3.2.   By Drug Class

            17.16.3.3.   By Distribution Channel

17.17. South Africa Rare Neurodegenerative Disease Treatment Market Analysis

        17.17.1. Pricing Analysis

        17.17.2. Market Value Proportion Analysis by Market Taxonomy

        17.17.3. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy

            17.17.3.1.   By Indication

            17.17.3.2.   By Drug Class

            17.17.3.3.   By Distribution Channel

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies (Rare Neurodegenerative Disease Treatment)

    18.2. Market Concentration

    18.3. Market Share Analysis of Top Players

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Competition Deep Dive 

        19.3.1. Allergan Plc

            19.3.1.1. Overview

            19.3.1.2. Product Portfolio

            19.3.1.3. Profitability by Market Segments (Product/Region)

            19.3.1.4. Sales Footprint

            19.3.1.5. Strategy Overview

        19.3.2. Bayer AG

            19.3.2.1. Overview

            19.3.2.2. Product Portfolio

            19.3.2.3. Profitability by Market Segments (Product/Region)

            19.3.2.4. Sales Footprint

            19.3.2.5. Strategy Overview

        19.3.3. F. Hoffmann-La Roche Ltd.

            19.3.3.1. Overview

            19.3.3.2. Product Portfolio

            19.3.3.3. Profitability by Market Segments (Product/Region)

            19.3.3.4. Sales Footprint

            19.3.3.5. Strategy Overview 

        19.3.4. GlaxoSmithKline Plc  

            19.3.4.1. Overview

            19.3.4.2. Product Portfolio

            19.3.4.3. Profitability by Market Segments (Product/Region)

            19.3.4.4. Sales Footprint

            19.3.4.5. Strategy Overview

        19.3.5. Johnson & Johnson

            19.3.5.1. Overview

            19.3.5.2. Product Portfolio

            19.3.5.3. Profitability by Market Segments (Product/Region)

            19.3.5.4. Sales Footprint

            19.3.5.5. Strategy Overview

        19.3.6. Merck KGaA  

            19.3.6.1. Overview

            19.3.6.2. Product Portfolio

            19.3.6.3. Profitability by Market Segments (Product/Region)

            19.3.6.4. Sales Footprint

            19.3.6.5. Strategy Overview

        19.3.7. Novartis AG

            19.3.7.1. Overview

            19.3.7.2. Product Portfolio

            19.3.7.3. Profitability by Market Segments (Product/Region)

            19.3.7.4. Sales Footprint

            19.3.7.5. Strategy Overview

        19.3.8. Pfizer Inc.

            19.3.8.1. Overview

            19.3.8.2. Product Portfolio

            19.3.8.3. Profitability by Market Segments (Product/Region)

            19.3.8.4. Sales Footprint

            19.3.8.5. Strategy Overview

        19.3.9. Sanofi

            19.3.9.1. Overview

            19.3.9.2. Product Portfolio

            19.3.9.3. Profitability by Market Segments (Product/Region)

            19.3.9.4. Sales Footprint

            19.3.9.5. Strategy Overview

        19.3.10. Teva Pharmaceuticals Industries Ltd.

            19.3.10.1. Overview

            19.3.10.2. Product Portfolio

            19.3.10.3. Profitability by Market Segments (Product/Region)

            19.3.10.4. Sales Footprint

            19.3.10.5. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Rare Neurodegenerative Disease Treatment Market Forecast, Trend, Analysis & Competition Tracking - Global Market Insights 2020 to 2030